loan

subject: Boehringer Ingelheim Gmbh: Pharmavitae Profile Now Available At Reportsandreports [print this page]

Dallas, TX: ReportsandReports announce Boehringer Ingelheim GmbH: PharmaVitae Profile Market Research Report in its Store.

Browse complete Report at http://www.reportsandreports.com/market-reports/boehringer-ingelheim-gmbh-pharmavitae-profile/

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector

Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook

Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant

Table Of Contents

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Boehringer Ingelheim: PharmaVitae forecasts at a glance 7

Strategic insight 8

Leading position in core markets 8

Focused therapeutic coverage following key successes 8

Specialization can restrict opportunities 9

New launches struggle to match the decline of existing products 10

Drag on growth as historical drivers turn to decline 10

Slowing growth highlights challenges beyond 2013 11

External product deals needed to extend growth 12

Historical reliance upon internal discoveries 12

Tougher competition for late-stage product deals 13

SWOT analysis 14

Strengths 14

Weaknesses 16

Opportunities 16

Threats 18

CHAPTER 3 QUARTERLY NEWS UPDATE 20

Key findings 20

Quarterly sales update, Q408 21

Product developments 23

Deals and alliances 26

Product deals 26

Technology deals 26

M&A activity 27

Company announcements 27

Future product milestones 28

CHAPTER 4 COMPANY INTRODUCTION 29

Key findings 29

Background 30

Current corporate structure 31

Prescription pharmaceuticals 31

Consumer healthcare 31

Industrial customer 32

Animal health 32

M&A history 33

CHAPTER 5 COMPANY SALES 34

Key findings 34

Prescription pharmaceutical sales and growth rate analysis, 2001-13 35

Product analysis 37

Product analysis, 2001-07 37

Product analysis, 2007-13 40

Therapy area analysis 44

Therapy area analysis, 2001-07 45

Therapy area analysis, 2007-13 47

Therapy area focus, 2001-13 50

Geographic analysis 52

Geographic analysis, 2001-07 53

Geographic analysis, 2007-13 54

Geographic focus, 2001-13 56

Launch/core/expiry analysis 58

Explanation of launch/core/expiry analysis 58

Launch analysis, 2007-13 59

Core analysis, 2007-13 62

Expiry analysis, 2007-13 64

Launch/core/expiry configuration, 2007-13 65

Molecule type analysis 68

Molecule type analysis, 2001-07 69

Molecule type analysis, 2007-13 70

Externalization analysis 73

Externalization analysis, 2001-07 74

Externalization analysis, 2007-13 76

CHAPTER 6 COMPANY FINANCIALS 80

Key findings 80

Reconciliation between PharmaVitae-formatted prescription pharma sales and company reported total sales, 2001-07 81

Financial statements, 2001-07 82

Profit and loss account, 2001-07 82

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 84

Key findings 84

Overview 85

Respiratory 86

Spiriva franchise 86

Overview 86

Sales forecast 87

Success driven by unique market position 87

Cardiovascular 89

Micardis franchise 89

Overview 89

Sales forecast 90

Uptake driven by best in class attributes 90

Growth maintained despite competition across 2007-13 91

Pradaxa 92

Overview 92

Sales forecast 93

Uptake driven by unmet need 93

Pradaxa may be adversely affected by DTI history 94

Competition will prevent a greater capture of market share 95

Urology & gender specific health 96

Flomax 96

Overview 96

Sales forecast 97

Market leading BPH treatment 97

Generic erosion dependent upon acheivment of pediatric exclusivity 98

Central nervous system 99

Sifrol/ Mirapex 99

Overview 99

Sales forecast 100

Historically positioned as a market leading treatment for Parkinson's disease 100

Late entry to once-daily market limits sales potential 101

CHAPTER 8 APPENDIX 103

R&D pipeline 103

References 111

Abbreviations 111

Exchange rates 112

List of Tables

Table 1: Boehringer Ingelheim: PharmaVitae forecasts at a glance 7

Table 2: Boehringer Ingelheim quarterly global sales update ($m), Q4 2008 21

Table 3: Boehringer Ingelheim key product developments, Q1-Q4 2008 23

Table 4: Boehringer Ingelheim product deals and alliances, Q1-Q4 2008 26

Table 5: Boehringer Ingelheim technology deals and alliances, Q1-Q4 2008 26

Table 6: Boehringer Ingelheim M&A activity, Q1-Q4 2008 27

Table 7: Boehringer Ingelheim company announcements, Q1-Q4 2008 27

Table 8: Boehringer Ingelheim future product milestones, 2008-10 28

Table 9: Boehringer Ingelheim's major consumer healthcare products 32

Table 10: Boehringer Ingelheim product portfolio overview ($m), 2001-07 37

Table 11: Boehringer Ingelheim product portfolio overview ($m), 2007-13 40

Table 12: Boehringer Ingelheim product portfolio overview ($m), 2001-07 45

Table 13: Boehringer Ingelheim product portfolio overview ($m), 2007-13 47

Table 14: Boehringer Ingelheim portfolio overview by geographic region ($m), 2001-07 53

Table 15: Boehringer Ingelheim portfolio overview by geographic region ($m), 2007-13 54

Table 16: Boehringer Ingelheim launch portfolio overview ($m), 2007-13 59

Table 17: Boehringer Ingelheim core portfolio overview ($m), 2007-13 62

Table 18: Boehringer Ingelheim expiry portfolio overview ($m), 2007-13 64

Table 19: Boehringer Ingelheim portfolio overview by molecule type ($m), 2001-07 69

Table 20: Boehringer Ingelheim product portfolio overview by molecule type ($m), 2007-13 70

Table 21: Boehringer Ingelheim product portfolio overview by source ($m), 2001-07 74

Table 22: Boehringer Ingelheim product portfolio overview by source ($m), 2007-13 76

Table 23: Total Boehringer Ingelheim sales by business unit ($m), 2001-07 81

Table 24: Boehringer Ingelheim profit and loss account ($m), 2001-07 82

Table 25: Key products overview 85

Table 26: Spiriva: overview 86

Table 27: Spiriva: sales forecast ($m), 2007-13 87

Table 28: Spiriva+salmeterol: sales forecast ($m), 2007-13 87

Table 29: Micardis: overview 89

Table 30: Micardis: sales forecast ($m), 2007-13 90

Table 31: Micardis HCT: sales forecast ($m), 2007-13 90

Table 32: Pradaxa: overview 92

Table 33: Pradaxa: sales forecast ($m), 2007-13 93

Table 34: Flomax: overview 96

Table 35: Flomax: sales forecast ($m), 2007-13 97

Table 36: Sifrol: overview 99

Table 37: Sifrol: sales forecast ($m), 2007-13 100

Table 38: Pramipexole ER: sales forecast ($m), 2007-13 100

Table 39: Boehringer Ingelheim's R&D pipeline (Phase I-registration) 103

Table 40: Exchange rates, 2007 112

List of Figures

Figure 1: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5

Figure 2: Boehringer Ingelheim operating revenue/cost analysis ($m), 2001-07 6

Figure 3: Boehringer Ingelheim prescription pharma sales by therapy area (% of total), 2001-13 8

Figure 4: Boehringer Ingelheim prescription pharmaceutical sales by product category ($m), 2001-13 11

Figure 5: Boehringer Ingelheim SWOT analysis 14

Figure 6: Top 10 product sales ($m), previous vs. update, 2008 22

Figure 7: Current corporate structure 31

Figure 8: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 35

Figure 9: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2001-07 38

Figure 10: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2007-13 41

Figure 11: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2001-13 44

Figure 12: Boehringer Ingelheim prescription pharma sales by therapy area (% of total), 2001-13 50

Figure 13: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 2001-13 52

Figure 14: Boehringer Ingelheim growth drivers and resistors by geographic region ($m), 2001-07 53

Figure 15: Boehringer Ingelheim drivers and resistors by geographic region ($m), 2007-13 55

Figure 16: Boehringer Ingelheim prescription pharmaceutical sales by geographic region (% of total), 2001-13 56

Figure 17: Boehringer Ingelheim launch/core/expiry configuration ($m), 2007-13 65

Figure 18: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 2001-13 68

Figure 19: Boehringer Ingelheim growth drivers and resistors by molecule type ($m), 2007-13 71

Figure 20: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 2001-13 73

Figure 21: Boehringer Ingelheim growth drivers and resistors by source ($m), 2001-07 74

Figure 22: Boehringer Ingelheim growth drivers and resistors by source ($m), 2007-13 78

Figure 23: Boehringer Ingelheim operating revenue/cost analysis ($m), 2001-07 83

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:

Boehringer Ingelheim GmbH - SWOT Analysis

Boehringer Ingelheim GmbH Market Share Analysis

Boehringer Ingelheim GmbH-Company Report

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

by: Ms.Sunita

welcome to loan (http://www.yloan.com/)